Portfoliotracker

Bicara Therapeutics Inc.

BCAX · NASDAQGM · Healthcare Biotechnology 23/100 E

9,750 $
▼ −0,270 (−2,69 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:11
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score23 / 100 Market cap667 mil. $ P/E– Forward P/E-2,6 P/S– P/B1,6 EV/EBITDA– Dividend yield– FCF yield-24,41 % EPS-3,46 $ Net margin0,0 % Return on equity-54,2 % Beta-0,34 Debt / equity0,00
52-week range 7,87 to 30,99
3-month average volume1,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Website
bicara.com
Employees
103
Country
United States
Fiscal year end
31. 12.
Data since
13. 9. 2024

Explore further

Similar companies MBXAVBPUPBRAPPZBIO

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account